Replies to post #175928 on Biotech Values

[caravon]

The article compares ECYT vs CLVS market caps but did not mentioned that CLVS has no partners to share its profit if successful. Therefore, for a better comparison, ECYT's MC has to be at least doubled for a "apples to apples" comparison.

[jq1234]

>> By contrast, Clovis is at least two years away from even submitting a regulatory filing for one of its clinical candidates,

That's not true. CLVS has guided regulatory filing by YE2015 for 2nd line EGFR+T790m NSCLC.

[GrthzGd]

Turning to Endocyte's fundamentals, ... I wouldn't expect a major secondary offering to be forthcoming in the near-term

Whoops!

Endocyte launches 4.5M-share offering • 5:10 PM

Endocyte's (ECYT) offering would yield gross proceeds of $121.5M at current levels. Underwriters will have a 675K-share overallotment option. (PR)
The drug developer had $159M in cash/investments at the end of 2013, and no debt.
ECYT -0.7% AH